tiprankstipranks
ArcticZymes Innovates Measles Virus Purification Process
Company Announcements

ArcticZymes Innovates Measles Virus Purification Process

ArcticZymes Technologies ASA (DE:B4V) has released an update.

Don't Miss Our Christmas Offers:

ArcticZymes Technologies ASA has showcased the impressive capabilities of its M-SAN HQ nuclease in enhancing the purification process of recombinant measles viruses, as highlighted in the Journal of Chromatography A. By integrating M-SAN HQ with heparin affinity chromatography, the company has significantly improved both the purity and yield of virus production, offering a more efficient and cost-effective solution for manufacturers. This advancement not only ensures higher product quality but also aids in meeting stringent regulatory standards, accelerating access to safe and effective therapies.

For further insights into DE:B4V stock, check out TipRanks’ Stock Analysis page.

Related Articles
TipRanks European Auto-Generated NewsdeskArcticZymes Enhances Biomanufacturing with New Innovations
TipRanks European Auto-Generated NewsdeskArcticZymes Highlights Growth at SEB Seminar
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App